| Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis (NCT02131285) | Fondazione Don Carlo Gnocchi ETS | 2005-01-01 |
| Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis (NCT00206635) | Bayer | 2005-01-01 |
| Biomarkers in Multiple Sclerosis (NCT00325988) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-12-17 |
| Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis (NCT00099307) | National Institute of Neurological Disorders and Stroke (NINDS) | 2004-12-08 |
| Multiple Sclerosis Rehabilitation Study (NCT00202254) | Melbourne Health | 2004-12-01 |
| A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis (NCT00097188) | Genentech, Inc. | 2004-12-01 |
| The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis (NCT00151294) | Weill Medical College of Cornell University | 2004-11-01 |
| Gene Expression in MS Patients Before and During Treatment With Interferon-beta (NCT00202384) | S. Andrea Hospital | 2004-11-01 |
| The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients (NCT00094068) | National Institutes of Health Clinical Center (CC) | 2004-10-01 |
| Efficacy and Safety of BG00012 in MS (NCT00168701) | Biogen | 2004-10-01 |
| EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis (NCT00137176) | University of North Carolina, Chapel Hill | 2004-10-01 |
| A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®. (NCT00240032) | Teva Branded Pharmaceutical Products R&D, Inc. | 2004-10-01 |
| EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis (NCT00146068) | University of North Carolina | 2004-09-01 |
| Restoration of Walking in Multiple Sclerosis Using Treadmill Training. (NCT00156676) | US Department of Veterans Affairs | 2004-09-01 |
| Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis (NCT00134563) | Sanofi | 2004-09-01 |
| A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®. (NCT00220922) | Teva Neuroscience, Inc. | 2004-08-01 |
| Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis (NCT00223301) | University of Texas Southwestern Medical Center | 2004-07-01 |
| A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis (NCT00207727) | Centocor, Inc. | 2004-07-01 |
| Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis (NCT00103974) | Bayhill Therapeutics | 2004-07-01 |
| An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis (NCT01142557) | Merck KGaA, Darmstadt, Germany | 2004-06-01 |
| A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis (NCT00087529) | Genentech, Inc. | 2004-06-01 |
| Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (NCT00493077) | Biogen | 2004-05-01 |
| Cannabis for Spasticity in Multiple Sclerosis (NCT00682929) | University of California, Davis | 2004-04-14 |
| Trial of Memantine for Cognitive Impairment in Multiple Sclerosis (NCT00300716) | Oregon Health and Science University | 2004-04-01 |
| A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis (NCT00217295) | Multiple Sclerosis Institute | 2004-04-01 |
| Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis (NCT00223457) | University of Texas Southwestern Medical Center | 2004-04-01 |
| Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) (NCT00086671) | AbbVie (prior sponsor, Abbott) | 2004-04-01 |
| Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS) (NCT00364936) | King's College London | 2004-03-01 |
| Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) (NCT00168714) | Biogen | 2004-02-01 |
| Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (NCT00666224) | Teva Branded Pharmaceutical Products R&D, Inc. | 2004-01-01 |
| Open-Label Natalizumab Safety Extension Study (NCT00276172) | Biogen | 2003-12-01 |
| Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis (NCT00246324) | Louisiana State University Health Sciences Center Shreveport | 2003-12-01 |
| Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis (NCT00654927) | Acorda Therapeutics | 2003-11-01 |
| Phase II High-Dose Cyclophosphamide for Multiple Sclerosis (NCT00296205) | Stony Brook University | 2003-10-01 |
| Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks (NCT00418145) | Fred Lublin | 2003-09-01 |
| Effects of Spinal Cord Injury on Female Sexual Response (NCT00142714) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2003-08-01 |
| A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers (NCT00913250) | Biogen | 2003-08-01 |
| Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) (NCT00079495) | Neurocrine Biosciences | 2003-07-01 |
| MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis (NCT00064909) | National Institutes of Health Clinical Center (CC) | 2003-07-01 |
| FOCUS Fatigue Outcome in Copaxone USers (NCT00267319) | Sanofi | 2003-06-01 |
| Modafinil in Multiple Sclerosis (NCT00142402) | Kessler Foundation | 2003-06-01 |
| Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis (NCT00278655) | Northwestern University | 2003-06-01 |
| A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy (NCT00238654) | Teva Neuroscience, Inc. | 2003-05-01 |
| Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (NCT00333138) | Novartis | 2003-05-01 |
| Lorraine Registry of Multiple Sclerosis (NCT02883335) | Central Hospital, Nancy, France | 2003-05-01 |
| Lido Workset Study (NCT00710645) | University of California, Davis | 2003-04-01 |
| Cannabis for Spasticity in Multiple Sclerosis (NCT00260741) | Center for Medicinal Cannabis Research | 2003-03-01 |
| Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis (NCT00053417) | Acorda Therapeutics | 2003-02-01 |
| Combination Therapy of Betaseron-Prograf in Multiple Sclerosis (NCT00298662) | Clinique de sclérose en plaques et neuromusculaire de l'Outaouais | 2003-02-01 |
| Safety of RG2077 in Patients With Multiple Sclerosis (NCT00076934) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-01-01 |
| Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study (NCT06705608) | University of British Columbia | 2003-01-01 |
| Immunogenicity and Safety Study of Serum-Free Avonex (NCT00912860) | Biogen | 2003-01-01 |
| Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (NCT00176592) | University of Medicine and Dentistry of New Jersey | 2003-01-01 |
| Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients (NCT00050232) | Avanir Pharmaceuticals | 2002-12-01 |
| Rebif® Pregnancy Registry (NCT00338741) | EMD Serono | 2002-12-01 |
| Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers (NCT00913666) | Biogen | 2002-11-01 |
| BEYOND Pilot Study (NCT00893217) | Bayer | 2002-11-01 |
| A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis (NCT00678795) | Jazz Pharmaceuticals | 2002-08-01 |
| BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study (NCT00185211) | Bayer | 2002-08-01 |
| Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis (NCT00599274) | Biogen | 2002-08-01 |
| Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity. (NCT00047580) | Elan Pharmaceuticals | 2002-06-01 |
| A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. (NCT00711646) | Jazz Pharmaceuticals | 2002-06-01 |
| Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (NCT00342134) | National Institute of Neurological Disorders and Stroke (NINDS) | 2002-05-01 |
| T Cell Vaccination in Patients With Progressive Multiple Sclerosis (NCT01448252) | Hadassah Medical Organization | 2002-05-01 |
| Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. (NCT00037115) | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | 2002-05-01 |
| TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis (NCT00228228) | Sheba Medical Center | 2002-05-01 |
| Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients (NCT00151801) | S. Andrea Hospital | 2002-05-01 |
| Testosterone Treatment for Multiple Sclerosis (NCT00405353) | University of California, Los Angeles | 2002-04-01 |
| A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin (NCT01606176) | Jazz Pharmaceuticals | 2002-03-01 |
| A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis (NCT01604265) | Jazz Pharmaceuticals | 2002-03-01 |
| A Study of the Long-term Safety of Sativex Use (NCT01606137) | Jazz Pharmaceuticals | 2002-02-01 |
| Serum Auto-Antibodies in Neurological Diseases (NCT00704626) | University of California, Davis | 2002-01-01 |
| Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (NCT00228163) | Sanofi | 2002-01-01 |
| Treatment of Multiple Sclerosis With Copaxone and Albuterol (NCT00039988) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-11-01 |
| A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis (NCT00035529) | Bristol-Myers Squibb | 2001-11-01 |
| Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis (NCT00202410) | S. Andrea Hospital | 2001-11-01 |
| Auditory Function in Patients With and Without Multiple Sclerosis (NCT00037947) | US Department of Veterans Affairs | 2001-10-01 |
| Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis (NCT00248378) | Center for Medicinal Cannabis Research | 2001-09-01 |
| Autologous Stem Cell Transplant for Multiple Sclerosis (NCT01099930) | Ottawa Hospital Research Institute | 2001-08-01 |
| Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis (NCT00037102) | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | 2001-07-01 |
| A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis (NCT01610687) | Jazz Pharmaceuticals | 2001-07-01 |
| An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis (NCT01610713) | Jazz Pharmaceuticals | 2001-05-01 |
| An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients (NCT01610700) | Jazz Pharmaceuticals | 2001-05-01 |
| Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis (NCT00017628) | Northwestern Memorial Hospital | 2001-04-01 |
| Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (NCT01487096) | Sanofi | 2001-04-01 |
| Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis (NCT00179478) | Beth Israel Deaconess Medical Center | 2001-02-01 |
| Rolipram to Treat Multiple Sclerosis (NCT00011375) | National Institute of Neurological Disorders and Stroke (NINDS) | 2001-02-01 |
| Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients (NCT00262314) | EMD Serono | 2000-10-01 |
| Exploring the Comorbidity Between Mental Disorders and General Medical Conditions (NCT03847753) | University of Aarhus | 2000-01-01 |
| Improving Memory in Patients With Multiple Sclerosis (NCT00062972) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1999-09-01 |
| Yoga: Effect on Attention in Aging & Multiple Sclerosis (NCT00010998) | National Center for Complementary and Integrative Health (NCCIH) | 1999-09-01 |
| Optimizing IFN Beta - 1B Dose (NCT00473213) | University of Turin, Italy | 1999-09-01 |
| Open-Label Safety Extension Study of Avonex (NCT00915460) | Biogen | 1999-09-01 |
| Natural Antioxidants in the Treatment of Multiple Sclerosis (NCT00010842) | National Center for Complementary and Integrative Health (NCCIH) | 1999-09-01 |
| Zenapax to Treat Multiple Sclerosis (NCT00001934) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-09-01 |
| Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis (NCT00006060) | National Center for Research Resources (NCRR) | 1999-04-01 |
| High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis (NCT00040482) | Baylor College of Medicine | 1999-04-01 |
| T-Cell Vaccination in Multiple Sclerosis (MS) (NCT00220428) | Sheba Medical Center | 1998-07-01 |
| Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS) (NCT00001781) | National Institute of Neurological Disorders and Stroke (NINDS) | 1998-02-01 |
| Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis (NCT00014755) | Fred Hutchinson Cancer Center | 1997-12-01 |